On March 23, 2026, Silexion Therapeutics Corp reconvened its extraordinary general meeting originally held on March 16, 2026, which had been adjourned due to a lack of quorum. At the reconvened meeting, shareholders representing approximately 36.6% of the company's issued and outstanding ordinary shares were present, either in person or by proxy. The primary agenda was to vote on two proposals: an increase to the authorized share capital and an amendment to the 2024 Equity Incentive Plan. The results showed that the proposal to increase the authorized share capital by 50 million ordinary shares was rejected, with 461,249 votes in favor (38.2%) and 744,775 votes against (61.8%). Similarly, the amendment to the 2024 Plan was also not approved, with 486,671 votes in favor (40.7%) and 709,115 votes against (59.3%). Neither proposal received the requisite affirmative vote of a simple majority, which is a significant setback for the company as it seeks to enhance its capital structure and incentivize its workforce. The failure to secure these approvals may impact Silexion's ability to raise funds and execute its strategic plans effectively, leading to potential liquidity challenges in the future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.